Pipeline

Medicines in Development

Tasly U.S., “Dedicated to a Healthier World,” has a range of  alternative medicines in development that are intended to address unmet health needs and offer disease prevention options in a number of key medical areas, including cardiovascular health, liver health, oncology, immunology and stem cell research.
 
AreasProgramClassificationIndicationDevelopment Stage  Status
PRE-CLINICAL PHASE I PHASE II PHASE III a PHASE III b
CardiovascularT89HerbalChronic stable angina
Phase III trial completed
CardiovascularT89HerbalChronic stable angina
Phase III ORESA study
ongoing
CardiovascularT89HerbalAcute mountain sickness (AMS)
Phase II T89-30-AMS trial completed; Phase III clinical trial will be initiated in Q2 of 2021
Oncology
TSL1502Small MoleculeOvarian cancer, prostate cancer, breast cancer, stomach cancer, and lung cancer, pancreatic cancer
IND granted by FDA in April 2019; Phase I study ongoing (in China)
Liver
HEPA44PolypeptideHepatitis B
Applying for an IND to conduct clinical trial in the U.S.
Stem cell
UMSC01Stem CellAcute myocardial infarction and ischemic stroke
A Phase I open label clinical trial is currently being performed with an estimated completion in 2021.
Immunology
TA06BiologicalAn innovative technology of enzymatic digestion, or sample deglycosylation, which significantly boosts anti-PD-L1 antibody binding affinity and signal intensity causing a more precise PD-L1 quantification and prediction of clinical outcome.